Correlation Between Cell Source and Virpax Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Cell Source and Virpax Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cell Source and Virpax Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cell Source and Virpax Pharmaceuticals, you can compare the effects of market volatilities on Cell Source and Virpax Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cell Source with a short position of Virpax Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cell Source and Virpax Pharmaceuticals.

Diversification Opportunities for Cell Source and Virpax Pharmaceuticals

0.24

Correlation Coefficient

Cell Source  Virpax Pharmaceuticals

Modest diversification

The 3 months correlation between Cell and Virpax is 0.24. Overlapping area represents the amount of risk that can be diversified away by holding Cell Source and Virpax Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virpax Pharmaceuticals and Cell Source is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cell Source are associated (or correlated) with Virpax Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virpax Pharmaceuticals has no effect on the direction of Cell Source i.e., Cell Source and Virpax Pharmaceuticals go up and down completely randomly.

Pair Corralation between Cell Source and Virpax Pharmaceuticals

Given the investment horizon of 90 days Cell Source is expected to generate 196.83 times less return on investment than Virpax Pharmaceuticals. But when comparing it to its historical volatility, Cell Source is 9.42 times less risky than Virpax Pharmaceuticals. It trades about 0.01 of its potential returns per unit of risk. Virpax Pharmaceuticals is currently generating about 0.12 of returns per unit of risk over similar time horizon. If you would invest  33.00  in Virpax Pharmaceuticals on December 20, 2024 and sell it today you would earn a total of  216.75  from holding Virpax Pharmaceuticals or generate 656.82% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	98.36%
Values	Daily Returns

Cell Source  vs.  Virpax Pharmaceuticals

Cell Source

Risk-Adjusted Performance

Very Weak

Over the last 90 days Cell Source has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Cell Source is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Virpax Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Virpax Pharmaceuticals are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Virpax Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Cell Source and Virpax Pharmaceuticals

The main advantage of trading using opposite Cell Source and Virpax Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cell Source position performs unexpectedly, Virpax Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virpax Pharmaceuticals will offset losses from the drop in Virpax Pharmaceuticals' long position.

The idea behind Cell Source and Virpax Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.